Vetr Upgrades Merrimack Following Earnings, Licensing Rumors By: Benzinga via Benzinga November 29, 2016 at 14:52 PM EST The Vetr crowd upgraded their rating for Merrimack Pharmaceuticals Inc (NASDAQ: MACK) from the previous rating of 2 stars (Sell), ... Read More >>